Senate Bill 204, which says an "Opioid treatment program" means a program or practitioner engaged in the treatment of ...

• Glucagon-like peptide 1 receptor agonists (GLP-1) (medicines used to lower blood glucose) probably reduce the risk of death due to any cause but may have little or no death due to a heart attack in ...

Total 4Q and full year 2024 net product revenue of $118.8 million and $385.7 million, respectively, representing 66% and 88% year-over-year ...

Who hasn't been there? The big meal is over, you're full, but the craving for sweets remains. Researchers from the Max Planck ...

New research sheds light on how ketamine affects the brain by targeting a specific NMDA receptor subtype, GluN1-2B-2D.

Who hasn't been there? The big meal is over, you're full, but the craving for sweets remains. Researchers have now discovered that what we call the 'dessert stomach' is rooted in the brain. The same ...

Who hasn't been there? The big meal is over, you're full, but the craving for sweets remains. Researchers from the Max Planck ...

In mice, the neurons that dictate the feeling of being full are also the ones that cause sugar cravings, potentially ...

Excluding people with type 2 diabetes from the trial might have resulted in a missed opportunity to establish whether people with both Parkinson's disease and type 2 diabetes could benefit from GLP-1 ...

HealthDay News — Glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is not associated with an increased risk for thyroid cancer over the short term, according to a study published online Jan. 16 ...

pK D values for 12 antagonists as determined from measurements of CRE-SPAP production from CHO-H3-cells made in the presence of the 12 different agonists. Values represent mean±s.e.mean of n ...

State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing 210023, P. R. China ...